{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:42:29Z","timestamp":1792057349205,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10549-022-06577-5","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:02:49Z","timestamp":1649073769000},"page":"417-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen"],"prefix":"10.1007","volume":"193","author":[{"given":"Brittany","family":"Bychkovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisher","family":"Katlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marybeth","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Knust Graichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia E.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Scheib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-2351","authenticated-orcid":false,"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"issue":"18","key":"6577_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"6577_CR2","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, Investigators NCMS (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381\u20132391. https:\/\/doi.org\/10.1056\/NEJMoa1103507","journal-title":"N Engl J Med"},{"issue":"6","key":"6577_CR3","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant B, Bowel P (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 3(6):696\u2013706. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0076","journal-title":"Cancer Prev Res (Phila)"},{"issue":"9922","key":"6577_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, Investigators I-I (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041\u20131048. https:\/\/doi.org\/10.1016\/S0140-6736(13)62292-8","journal-title":"Lancet"},{"issue":"1","key":"6577_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, Investigators I-I (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)71171-4","journal-title":"Lancet Oncol"},{"issue":"19","key":"6577_CR6","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Buttiron Webber T, Boni L, Bonanni B (2019) Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 37(19):1629\u20131637. https:\/\/doi.org\/10.1200\/JCO.18.01779","journal-title":"J Clin Oncol"},{"issue":"33","key":"6577_CR7","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.19.01472","volume":"37","author":"K Visvanathan","year":"2019","unstructured":"Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR (2019) Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol 37(33):3152\u20133165. https:\/\/doi.org\/10.1200\/JCO.19.01472","journal-title":"J Clin Oncol"},{"issue":"7","key":"6577_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","volume":"8","author":"ER Port","year":"2001","unstructured":"Port ER, Montgomery LL, Heerdt AS, Borgen PI (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8(7):580\u2013585. https:\/\/doi.org\/10.1007\/s10434-001-0580-9","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"6577_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","volume":"119","author":"A Fagerlin","year":"2010","unstructured":"Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA (2010) Women\u2019s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 119(3):613\u2013620. https:\/\/doi.org\/10.1007\/s10549-009-0618-4","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"6577_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1370\/afm.284","volume":"3","author":"R Taylor","year":"2005","unstructured":"Taylor R, Taguchi K (2005) Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3(3):242\u2013247. https:\/\/doi.org\/10.1370\/afm.284","journal-title":"Ann Fam Med"},{"issue":"4","key":"6577_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J (2016) Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 27(4):575\u2013590. https:\/\/doi.org\/10.1093\/annonc\/mdv590","journal-title":"Ann Oncol"},{"issue":"18","key":"6577_CR12","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","volume":"28","author":"ME Ropka","year":"2010","unstructured":"Ropka ME, Keim J, Philbrick JT (2010) Patient decisions about breast cancer chemoprevention\u202f: a systematic review and meta-analysis. J Clin Oncol 28(18):3090\u20133095. https:\/\/doi.org\/10.1200\/JCO.2009.27.8077","journal-title":"J Clin Oncol"},{"issue":"24","key":"6577_CR13","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1200\/JCO.2004.05.192","volume":"22","author":"SL Bober","year":"2004","unstructured":"Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22(24):4951\u20134957. https:\/\/doi.org\/10.1200\/JCO.2004.05.192","journal-title":"J Clin Oncol"},{"key":"6577_CR14","first-page":"624","volume":"52","author":"R Heisey","year":"2006","unstructured":"Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N (2006) Women\u2019s views on chemoprevention of breast cancer: qualitative study. Can Fam Phys 52:624\u2013625","journal-title":"Can Fam Phys"},{"issue":"1","key":"6577_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-018-05116-5","volume":"175","author":"A Weiss","year":"2019","unstructured":"Weiss A, Grossmith S, Cutts D, Mikami SA, Suskin JA, Graichen MK, Rojas NA, Pace LE, Joyce E, Rhei E, Scheib R, Bychkovsky B, Garber JE, Morganstern D, King TA (2019) Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Res Treat 175(1):229\u2013237. https:\/\/doi.org\/10.1007\/s10549-018-05116-5","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"6577_CR16","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1245\/s10434-019-07236-8","volume":"26","author":"MR Flanagan","year":"2019","unstructured":"Flanagan MR, Zabor EC, Stempel M, Mangino DA, Morrow M, Pilewskie ML (2019) Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann Surg Oncol 26(7):2127\u20132135. https:\/\/doi.org\/10.1245\/s10434-019-07236-8","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6577_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/tbj.13064","volume":"25","author":"CA Roche","year":"2019","unstructured":"Roche CA, Tang R, Coopey SB, Hughes KS (2019) Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast J 25(2):190\u2013195. https:\/\/doi.org\/10.1111\/tbj.13064","journal-title":"Breast J"},{"key":"6577_CR18","unstructured":"Afimoxifene in reducing the risk of breast cancer in women with mammographically dense breast. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03063619. Accessed 15 Sept 2020"},{"issue":"23","key":"6577_CR19","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/jco.2013.49.3122","volume":"31","author":"K Visvanathan","year":"2013","unstructured":"Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(23):2942\u20132962. https:\/\/doi.org\/10.1200\/jco.2013.49.3122","journal-title":"J Clin Oncol"},{"issue":"10","key":"6577_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7326\/0003-4819-159-10-201311190-00717","volume":"159","author":"VA Moyer","year":"2013","unstructured":"Moyer VA, USPST Force (2013) Medications to decrease the risk for breast cancer in women: recommendations from the US Preventive Services Task Force recommendation statement. Ann Intern Med 159(10):698\u2013708. https:\/\/doi.org\/10.7326\/0003-4819-159-10-201311190-00717","journal-title":"Ann Intern Med"},{"key":"6577_CR21","unstructured":"Bevers TB, Ward JH, Ahrendt G, Arun BK, Cohen JG, Colditz GA, al. e NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Risk Reduction. Version 1.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_risk.pdf. Accessed 13 July 2021."},{"issue":"7","key":"6577_CR22","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/bjc.2014.109","volume":"110","author":"LS Donnelly","year":"2014","unstructured":"Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, Juraskova I, Stavrinos P, Dawe S, Cuzick J, Howell A (2014) Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer 110(7):1681\u20131687. https:\/\/doi.org\/10.1038\/bjc.2014.109","journal-title":"Br J Cancer"},{"key":"6577_CR23","unstructured":"Study of Web-based Decision Aids for Increasing Breast Cancer Chemoprevention in the Primary Care Setting. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03069742. Accessed 5 Jan 2022"},{"key":"6577_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canep.2016.07.018","volume":"45","author":"BR Hunt","year":"2016","unstructured":"Hunt BR, Hurlbert MS (2016) Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005\u20132014. Cancer Epidemiol 45:169\u2013173. https:\/\/doi.org\/10.1016\/j.canep.2016.07.018","journal-title":"Cancer Epidemiol"},{"key":"6577_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx030","author":"A Jemal","year":"2017","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual Report to the Nation on the Status of Cancer, 1975\u20132014 featuring survival. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx030","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"6577_CR26","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.2015.66.0019","volume":"34","author":"AM McCarthy","year":"2016","unstructured":"McCarthy AM, Bristol M, Domchek SM, Groeneveld PW, Kim Y, Motanya UN, Shea JA, Armstrong K (2016) Health care segregation, physician recommendation, and racial disparities in BRCA1\/2 testing among women with breast cancer. J Clin Oncol 34(22):2610\u20132618. https:\/\/doi.org\/10.1200\/JCO.2015.66.0019","journal-title":"J Clin Oncol"},{"issue":"2","key":"6577_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37546","volume":"4","author":"CI Lee","year":"2021","unstructured":"Lee CI, Zhu W, Onega T, Henderson LM, Kerlikowske K, Sprague BL, Rauscher GH, O\u2019Meara ES, Tosteson ANA, Haas JS, diFlorio-Alexander R, Kaplan C, Miglioretti DL (2021) Comparative access to and use of digital breast tomosynthesis screening by women\u2019s race\/ethnicity and socioeconomic status. JAMA Netw Open 4(2):e2037546. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37546","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6577_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cncr.29805","volume":"122","author":"JS Haas","year":"2016","unstructured":"Haas JS, Hill DA, Wellman RD, Hubbard RA, Lee CI, Wernli KJ, Stout NK, Tosteson AN, Henderson LM, Alford-Teaster JA, Onega TL (2016) Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer 122(4):611\u2013617. https:\/\/doi.org\/10.1002\/cncr.29805","journal-title":"Cancer"},{"issue":"13","key":"6577_CR29","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1158\/1078-0432.CCR-20-4213","volume":"27","author":"A DeCensi","year":"2021","unstructured":"DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B (2021) Effect modifiers of low-dose tamoxifen in a randomized trial in breast noninvasive disease. Clin Cancer Res 27(13):3576\u20133583. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4213","journal-title":"Clin Cancer Res"},{"key":"6577_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cancers13020302","volume":"13","author":"M Eriksson","year":"2021","unstructured":"Eriksson M, Czene K, Conant EF, Hall P (2021) Use of low-dose tamoxifen to increase mammographic screening sensitivity in premenopausal women. Cancers (Basel) 13:2. https:\/\/doi.org\/10.3390\/cancers13020302","journal-title":"Cancers (Basel)"},{"issue":"9","key":"6577_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jama.2019.11885","volume":"322","author":"USPST Force","year":"2019","unstructured":"Force USPST, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB (2019) Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA 322(9):857\u2013867. https:\/\/doi.org\/10.1001\/jama.2019.11885","journal-title":"JAMA"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06577-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:48:37Z","timestamp":1744184917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06577-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6577"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06577-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.E.G. reports institutional research funding from Myriad Genetics, Ambry Genetics, and Invitae Genetics; consulting for Helix Genetics (compensation) and Earli (no compensation); leading two clinical trials for Astra-Zeneca; serving on the scientific advisory board of Konica Minolta (no compensation); conducting a sponsored lecture for Clinical Care Options, LLC; Editorial Services publications, President, Fellows of the AACR Academy, and member, Foundation Board of the American Association for Cancer Research; co-scientific director, Breast Cancer Research Foundation; board of directors, Facing Our Risk of Cancer Empowered; spousal consulting fees from Novartis Oncology, GTx Pharmaceuticals, Aleta BioTherapeutics and H3 Biomedicine, Inc.; a spousal advisory board membership at Oric Pharmaceuticals; and spousal scientific advisory board memberships at Kronos Bio, Susan G. Komen for the Cure, James P. Wilmot Foundation, Inc., Diane Helis Henry Medical Research Foundation, Adrienne Helis Melvin Medical Research Foundation, and Global Biological Standards Institute. T.K. reports speakers honoraria and advisory board for Exact Sciences (formerly Genomic Health); Faculty \u2013 PrecisCa Cancer information service; and serving on the Global advisory board for Besins Healthcare . All remaining authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the IRB of Brigham and Women\u2019s Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was approved by the Brigham and Women\u2019s Institutional Review Board as a low-risk study and approved with a waiver of consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Waiver of consent"}}]}}